115 results
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
29 Feb 24
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
7:35am
global launches and reimbursement approvals for selinexor by partners in ex-U.S. territories.
2024 Financial Outlook
Based on its current operating
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
8 Jan 24
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
8:40am
in more than 40 countries and recently achieved national reimbursement in mainland China. In 1Q 2023, the Company’s license agreement with the Menarini … , driving increased XPOVIO revenues.
Continue global launches and reimbursement approvals for selinexor by partners in ex-U.S. territories.
Listen
8-K
EX-99.1
bg0ssen4v6jr92 ljq0n
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
eckqx3r
1 Sep 23
Departure of Directors or Certain Officers
8:06am
8-K
EX-99.1
hnv idpwyl0w3dd
2 Aug 23
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
d5f5g 6dit
4 May 23
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:53am
8-K
EX-3.1
n5v1hph
2 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:05pm